Skip to main content
. 2024 Jun 6;13(12):e032971. doi: 10.1161/JAHA.123.032971

Figure 5. Amelioration of diastolic dysfunction, myocardial perfusion, and fibrosis are associated with increased levels of eNOS and its activating phosphorylation.

Figure 5

LV tissue levels of peNOS ser 1177 by Western blot analysis (A, upper part), densitometric analysis of peNOS ser 1177 levels (B), LV tissue levels of total eNOS by Western blot analysis (A lower part), densitometric analysis of eNOS levels (C), and the peNOS ser 1177/eNOS total ratio (D) from long‐term treatment (Protocol 2). LV tissue levels of peNOS ser 1177 by Western blot analysis (E, upper part), densitometric analysis of peNOS ser 1177 levels (F), LV tissue levels of total eNOS by Western blot analysis (E, lower part), densitometric analysis of eNOS levels (G), and the peNOS ser 1177/eNOS total ratio (H) from short‐term treatment (Protocol 3). ANOVA was used for statistical analysis of long‐term treatment and Student's t test for short‐term treatment, n=7–9. *P<0.05, **P<0.001, ***P<0.0001. CKD indicates chronic kidney disease; eNOS, endothelial nitric oxide synthase; Fine, finerenone; LV, left ventricular; and peNOS ser 1177, endothelial nitric oxide synthase and its activating phosphorylation.